FGFR1 is an adverse outcome indicator for luminal A breast cancers
نویسندگان
چکیده
منابع مشابه
FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11-12 amplification in breast cancer and its therapeutic/ prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Therefore, analysis of protein level may have more clinical relevance. We evaluated FGFR1 expression i...
متن کاملIsolated oligohydramnios is not an indicator for adverse perinatal outcome.
OBJECTIVES To assess the impact of isolated oligohydramnios on Perinatal outcomes. METHODS A prospective Cohort Study was conducted at the department of Obstetrics and Gynaecology, The Aga Khan University Hospital, Karachi, Pakistan. Pregnant women with isolated oligohydramnios were recruited for the study after obtaining informed consent. The mode of delivery and perinatal outcome were compa...
متن کاملAdjuvant chemotherapy in luminal breast cancers.
Luminal breast cancers are traditionally considered to comprise of tumors expressing estrogen receptor (ER) and represent the majority of breast cancers. These tumors are characterized by significant heterogeneity in phenotype, molecular signature, relapse patterns and therapeutic response to endocrine and chemotherapy. Whilst adjuvant endocrine therapy is standard of care in patients with tumo...
متن کاملHER2 status and disparities in luminal breast cancers
National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic differences among patients with HR+ breast cancer subtypes, and the role of HER2 status, age, race/eth...
متن کاملPrognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers
Aim To study the prognostic value of immunohistochemically detected low Claudin3 expression in breast cancers. Methods This retrospective study included patients with breast cancer who were investigated at our unit from 2006 to 2015. Tissue microarrays were constructed, and immunohistochemical staining was done to assess the Claudin3 expression and to classify breast cancers according to the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2015
ISSN: 1949-2553
DOI: 10.18632/oncotarget.6563